Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Invir.IO

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Published 26 November 2020
Categorized as -others, 2020, Invir.IO, Publication

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

Published 26 November 2020
Categorized as -others, 2020, Invir.IO, Publication

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201109 Transgene BioInvent_SITC BT001_EN

Published 9 November 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002

20200908 Transgene TG6002 Phase 1 EN

Published 8 September 2020
Categorized as -others, 2020, Invir.IO, Press release, TG6002

Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects

AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, Invir.IO, Publication

Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models

20200622b – BT-001_AACR poster EN

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors

20200515 BT-001_AACR curtain raiser EN

Published 15 May 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

20191211 PR preclinical BT001 EN

Published 11 December 2019
Categorized as 2019, BT-001, Invir.IO, Press release

Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming

Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation

Published 6 November 2019
Categorized as -others, 2019, Invir.IO, Publication

Posts pagination

Newer posts Page 1 … Page 4 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu